Evidence mapPaperPMID 33687591Full record

ArticleMolecular diversity2021

A novel artificial intelligence protocol to investigate potential leads for diabetes mellitus.

Jia-Ning Gong, Lu Zhao, Guanxing Chen, Xu Chen, Zhi-Dong Chen, Calvin Yu-Chian Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. On Approximating theBiomedicines · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jia-Ning Gong *Artificial Intelligence Medical Center, School of Intelligent Systems Engineering, Sun Yat-Sen University, Shenzhen, 510275, China.
Lu Zhao *Artificial Intelligence Medical Center, School of Intelligent Systems Engineering, Sun Yat-Sen University, Shenzhen, 510275, China.
Guanxing Chen *Artificial Intelligence Medical Center, School of Intelligent Systems Engineering, Sun Yat-Sen University, Shenzhen, 510275, China.
Xu Chen *Artificial Intelligence Medical Center, School of Intelligent Systems Engineering, Sun Yat-Sen University, Shenzhen, 510275, China.
Zhi-Dong Chen *Artificial Intelligence Medical Center, School of Intelligent Systems Engineering, Sun Yat-Sen University, Shenzhen, 510275, China.
Calvin Yu-Chian ChenArtificial Intelligence Medical Center, School of Intelligent Systems Engineering, Sun Yat-Sen University, Shenzhen, 510275, China. chenyuchian@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0001-9213-9832
Sun Yat-sen University · CNAsia University · TW

Funding

Guangzhou science and technology fund Grant No 201803010072Science, Technology, &Innovation Commission of Shenzhen Municipality JCYL 20170818165305521
6 · The paper itself

Abstract

Dipeptidyl peptidase-4 (DPP4) is highly participated in regulating diabetes mellitus (DM), and inhibitors of DPP4 may act as potential DM drugs. Therefore, we performed a novel artificial intelligence (AI) protocol to screen and validate the potential inhibitors from Traditional Chinese Medicine Database. The potent top 10 compounds were selected as candidates by Dock Score. In order to further screen the candidates, we used numbers of machine learning regression models containing support vector machines, bagging, random forest and other regression algorithms, as well as deep neural network models to predict the activity of the candidates. In addition, as a traditional method, 2D QSAR (multiple linear regression) and 3D QSAR methods are also applied. The AI methods got a better performance than the traditional 2D QSAR method. Moreover, we also built a framework composed of deep neural networks and transformer to predict the binding affinity of candidates and DPP4. Artificial intelligence methods and QSAR models illustrated the compound, 2007_4105, was a potent inhibitor. The 2007_4105 compound was finally validated by molecular dynamics simulations. Combining all the models and algorithms constructed and the results, Hypecoum leptocarpum might be a potential and effective medicine herb for the treatment of DM.

Indexed as

AlgorithmsArtificial IntelligenceDrug DesignBinding SitesDipeptidyl-Peptidase IV InhibitorsDrug DiscoveryHumansHydrogen BondingHypoglycemic AgentsMachine LearningMolecular Docking SimulationMolecular Dynamics SimulationMolecular StructureNeural Networks, ComputerProtein BindingQuantitative Structure-Activity RelationshipDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsArtificial intelligence (AI)Dipeptidyl peptidase-4 (DPP4)Machine learning (ML)Molecular dynamics simulation (MD)Quantitative structure–activity relationship (QSAR)

Identifiers

PMID33687591
OpenAlexW3135678680

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.